

Giuseppe Cimino

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6119034/publications.pdf>

Version: 2024-02-01

147
papers

6,858
citations

87888

38
h-index

62596

80
g-index

147
all docs

147
docs citations

147
times ranked

6572
citing authors

#	ARTICLE	IF	CITATIONS
1	Geographic distribution and phenotype of European people with cystic fibrosis carrying A1006E mutation. <i>Respiratory Medicine</i> , 2022, 192, 106736.	2.9	0
2	Elexacaftor/tezacaftor/ivacaftor in children aged 6–11 years with cystic fibrosis, at least one <i>F508DEL</i> allele, and advanced lung disease: A 24-week observational study. <i>Pediatric Pulmonology</i> , 2022, 57, 2253-2256.	2.0	9
3	Daratumumab triplet therapies in patients with relapsed or refractory Multiple Myeloma: a real-world experience. <i>Leukemia Research Reports</i> , 2022, , 100330.	0.4	2
4	SARS-CoV-2 Entry Genes Expression in Relation with Interferon Response in Cystic Fibrosis Patients. <i>Microorganisms</i> , 2021, 9, 93.	3.6	4
5	Cystic Fibrosis: Recent Insights into Inhaled Antibiotic Treatment and Future Perspectives. <i>Antibiotics</i> , 2021, 10, 338.	3.7	50
6	Stunning Response with Low-Dose Enzalutamide after Abiraterone Acetate Failure in a Patient Diagnosed with Metastatic Castration-Resistant Prostate Cancer: A Case Report. <i>Case Reports in Oncology</i> , 2021, 14, 634-640.	0.7	3
7	miR-125b/NRF2/HO-1 axis is involved in protection against oxidative stress of cystic fibrosis: A pilot study. <i>Experimental and Therapeutic Medicine</i> , 2021, 21, 585.	1.8	6
8	Assessment of Resistance Mechanisms and Clinical Implications in Patients with KRAS Mutated-Metastatic Breast Cancer and Resistance to CDK4/6 Inhibitors. <i>Cancers</i> , 2021, 13, 1928.	3.7	14
9	Unexpected cause of pancytopenia in a teenager with Noonan syndrome. <i>EJHaem</i> , 2021, 2, 642-643.	1.0	0
10	Prognostic impact of <i>KMT2A</i> positivity in 926 <i>BCR-ABL1</i> negative B-lineage acute lymphoblastic leukemia patients treated in GIMEMA clinical trials since 1996. <i>American Journal of Hematology</i> , 2021, 96, E334-E338.	4.1	3
11	Acute promyelocytic leukemia (APL) in very old patients: real-life behind protocols. <i>Acta Oncologica</i> , 2021, 60, 1520-1526.	1.8	2
12	Early response to caplacizumab and rituximab after anaphylaxis to Octaplas plasma in a patient with thrombotic thrombocytopenic purpura. <i>Journal of Clinical Apheresis</i> , 2021, 36, 499-504.	1.3	3
13	Astonishing response to Cetuximab in metastatic nasopharyngeal carcinoma: a case report. <i>Clinica Terapeutica</i> , 2021, 172, 260-263.	0.3	1
14	PD-L1 Expression on Circulating Tumour Cells May Be Predictive of Response to Regorafenib in Patients Diagnosed with Chemorefractory Metastatic Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6907.	4.1	11
15	Alectinib in the treatment of ocular metastases of ALK rearranged non small cell lung cancer. <i>Medicine (United States)</i> , 2020, 99, e21004.	1.0	4
16	Synchronous and Metachronous Metastatic Breast Cancer, with Different Histology and Opposite Immunophenotype, Treated with Combination of Chemotherapy, Anti-Her2, and Endocrine Therapy: A Case Report. <i>Case Reports in Oncology</i> , 2020, 13, 544-549.	0.7	5
17	Differential toll like receptor expression in cystic fibrosis patients' airways during rhinovirus infection. <i>Journal of Infection</i> , 2020, 81, 726-735.	3.3	4
18	Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. <i>Cancer Medicine</i> , 2020, 9, 8468-8479.	2.8	12

#	ARTICLE	IF	CITATIONS
19	Genetic lesions disrupting calreticulin 3â€™â€untranslated region in <scp>JAK2</scp> mutationâ€™negative polycythemia <scp>vera</scp>. American Journal of Hematology, 2020, 95, E263.	4.1	9
20	Herpes zoster granulomatous dermatitis in metastatic lung cancer treated with nivolumab: A case report. Thoracic Cancer, 2020, 11, 1330-1333.	1.9	9
21	Acute Promyelocytic Leukemia After Radium-223 Exposure for Prostate Cancer in a Chemotherapy-Naïve Patient. Nuclear Medicine and Molecular Imaging, 2020, 54, 256-260.	1.0	1
22	No detection of SARS-CoV-2 in cystic fibrosis patients at the Regional (Lazio) Reference Center for CF in Italy. Journal of Cystic Fibrosis, 2020, 19, 837-838.	0.7	8
23	Hodgkin lymphoma in pregnancy: good news for clinicians and women. Lancet Haematology,the, 2019, 6, e541-e542.	4.6	1
24	Comparison of 18F FDG PET-CT AND CECT in pretreatment staging of adults with Hodgkinâ€™s lymphoma. Leukemia Research, 2019, 76, 48-52.	0.8	6
25	Identification and monitoring of atypicalPML/RARafusion transcripts in acute promyelocytic leukemia. Genes Chromosomes and Cancer, 2019, 58, 60-65.	2.8	14
26	Acute Promyelocytic Leukemia (APL) in Very Elderly Patients: Real-Life behind Protocols. Blood, 2019, 134, 3845-3845.	1.4	1
27	Prognostic factors for thrombosis-free survival and overall survival in polycythemia vera: A retrospective analysis of 623 PTS With long follow-up. Leukemia Research, 2018, 69, 18-23.	0.8	2
28	Immunotherapy in Multiple Myeloma: Experience of the Multiple Myeloma Gimema Lazio Group. Blood, 2018, 132, 5634-5634.	1.4	0
29	Efficacy of Extracorporeal Photopheresis in Patients With Bronchiolitis Obliterans Syndrome After Lung Transplantation. Transplantation Proceedings, 2017, 49, 695-698.	0.6	17
30	Patients with classical Hodgkin lymphoma (CHL) and treatment failure despite a negative iPET have poor outcomes as patients with positive iPET and treatment escalation. Hematological Oncology, 2017, 35, 313-315.	1.7	0
31	High platelet count at diagnosis is a protective factor for thrombosis in patients with essential thrombocythemia. Thrombosis Research, 2017, 156, 168-171.	1.7	9
32	Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms. American Journal of Hematology, 2017, 92, 187-195.	4.1	41
33	A POPULATION-BASED STUDY ON MYELODYSPLASTIC SYNDROMES IN THE LAZIO REGION (ITALY), MEDICAL MISCODING AND 11-YEAR MORTALITY FOLLOW-UP: THE GRUPPO ROMANO-LAZIALE MIELODISPLASIE EXPERIENCE OF RETROSPECTIVE MULTICENTRIC REGISTRY. Mediterranean Journal of Hematology and Infectious Diseases. 2016, 9, e2017046.	1.3	3
34	<i>â€™Real Lifeâ€™</i>experience in a â€™difficult to treatâ€™patient population of non-Hodgkin lymphomas, using the R-COMP regimen. Leukemia and Lymphoma, 2016, 57, 2919-2922.	1.3	1
35	Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patients. American Journal of Hematology, 2016, 91, 318-321.	4.1	28
36	Do malignant diseases affect semen quality? Sperm parameters of men with cancers. Andrologia, 2016, 48, 333-340.	2.1	37

#	ARTICLE	IF	CITATIONS
37	Tapentadol prolonged release for patients with multiple myeloma suffering from moderate-to-severe cancer pain due to bone disease. <i>Journal of Pain Research</i> , 2015, 8, 229.	2.0	22
38	A Genotypic-Oriented View of CFTR Genetics Highlights Specific Mutational Patterns Underlying Clinical Macrocategories of Cystic Fibrosis. <i>Molecular Medicine</i> , 2015, 21, 257-275.	4.4	29
39	Acute promyelocytic leukemia in patients aged >70 years: the cure beyond the age. <i>Annals of Hematology</i> , 2015, 94, 195-200.	1.8	15
40	Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease. <i>Leukemia</i> , 2015, 29, 1360-1365.	7.2	57
41	Hemoglobin levels and circulating blasts are two easily evaluable diagnostic parameters highly predictive of leukemic transformation in primary myelofibrosis. <i>Leukemia Research</i> , 2015, 39, 314-317.	0.8	11
42	Anti-CD20 Therapy Acts via Fc γ RIIIA to Diminish Responsiveness of Human Natural Killer Cells. <i>Cancer Research</i> , 2015, 75, 4097-4108.	0.9	46
43	<i>Burkholderia pyrrocinia</i> in Cystic Fibrosis Lung Transplantation: A Case Report. <i>Transplantation Proceedings</i> , 2014, 46, 295-297.	0.6	5
44	A highly specific q-RT-PCR assay to address the relevance of the JAK2WT and JAK2V617F expression levels and control genes in Ph-negative myeloproliferative neoplasms. <i>Annals of Hematology</i> , 2014, 93, 609-616.	1.8	5
45	Thrombosis and survival in essential thrombocythemia: A regional study of 1,144 patients. <i>American Journal of Hematology</i> , 2014, 89, 542-546.	4.1	33
46	Arterial and venous thrombosis in patients with monoclonal gammopathy of undetermined significance: incidence and risk factors in a cohort of 1491 patients. <i>British Journal of Haematology</i> , 2013, 160, 673-679.	2.5	23
47	Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols. <i>Blood</i> , 2012, 119, 49-54.	1.4	63
48	Hepatitis B reactivation despite entecavir prophylaxis in a patient with chronic lymphocytic leukaemia receiving bendamustine. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 510-511.	3.0	5
49	Polycombs and microRNA-223 regulate human granulopoiesis by transcriptional control of target gene expression. <i>Blood</i> , 2012, 119, 4034-4046.	1.4	139
50	Prognostic factors associated with progression of smoldering multiple myeloma to symptomatic form. <i>Cancer</i> , 2012, 118, 5544-5549.	4.1	15
51	Subclinical Anthracycline Cardiotoxicity in Patients With Acute Promyelocytic Leukemia in Long-Term Remission After the AIDA Protocol. <i>Congestive Heart Failure</i> , 2012, 18, 217-221.	2.0	33
52	Role of PET/CT in the Diagnostic Work-up of Patients with Chronic Lymphocytic Leukemia (CLL) and Clinical Signs of Disease Progression. <i>Blood</i> , 2012, 120, 3888-3888.	1.4	1
53	The Role of Previous Thrombotic Events in Patients with Essential Thrombocythemia: The Earlier the Worse?. <i>Blood</i> , 2012, 120, 5062-5062.	1.4	0
54	Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Blood</i> , 2011, 118, 6521-6528.	1.4	395

#	ARTICLE	IF	CITATIONS
55	GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factors. <i>British Journal of Haematology</i> , 2011, 154, 564-568.	2.5	22
56	Multiple thromboembolism with multiple causes in a 69-year-old woman: a case report. <i>Journal of Medical Case Reports</i> , 2011, 5, 186.	0.8	2
57	Clinical outcome and monitoring of minimal residual disease in patients with acute lymphoblastic leukemia expressing the <i>MLL/ENL</i> fusion gene. <i>American Journal of Hematology</i> , 2011, 86, 993-997.	4.1	4
58	Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis. <i>Haematologica</i> , 2011, 96, 552-557.	3.5	84
59	Current trends in management of hepatitis B virus reactivation in the biologic therapy era. <i>World Journal of Gastroenterology</i> , 2011, 17, 3881.	3.3	51
60	Antiviral treatment including entecavir plus tenofovir disoproxil fumarate for HBV reactivation following a rituximab-based regimen. <i>Antiviral Therapy</i> , 2010, 15, 929-932.	1.0	17
61	Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. <i>Blood</i> , 2010, 116, 3171-3179.	1.4	290
62	Solitary plasmacytoma of tibia: A possible correlation with younger age. <i>Leukemia Research</i> , 2010, 34, e181-e182.	0.8	5
63	Evaluation of a home telemonitoring service for adult patients with cystic fibrosis: a pilot study. <i>Journal of Telemedicine and Telecare</i> , 2010, 16, 359-362.	2.7	28
64	The therapeutic response and clinical outcome of adults with ALL1(MLL)/AF4 fusion positive acute lymphoblastic leukemia according to the GIMEMA experience. <i>Haematologica</i> , 2010, 95, 837-840.	3.5	12
65	Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in Elderly acute myeloid leukaemia patients. <i>Hematological Oncology</i> , 2009, 27, 148-153.	1.7	38
66	Increasing the BCR-ABL expression levels and/or the occurrence of ABL point mutations does not always predict resistance to Imatinib Mesylate in BCR-ABL positive acute lymphoblastic leukemia. <i>Leukemia Research</i> , 2009, 33, e73-e74.	0.8	1
67	<i>IKZF1</i> (Ikaros) Deletions in <i>BCR-ABL1</i> Positive Acute Lymphoblastic Leukemia Are Associated With Short Disease-Free Survival and High Rate of Cumulative Incidence of Relapse: A GIMEMA AL WP Report. <i>Journal of Clinical Oncology</i> , 2009, 27, 5202-5207.	1.6	276
68	ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN PATIENTS AGED > 70 Years.. <i>Blood</i> , 2009, 114, 4160-4160.	1.4	0
69	Epigenetic plasticity of chromatin in embryonic and hematopoietic stem/progenitor cells: therapeutic potential of cell reprogramming. <i>Leukemia</i> , 2008, 22, 1503-1518.	7.2	55
70	An acute promyelocytic leukaemia patient with a new atypical promyelocytic leukemia breakpoint. <i>British Journal of Haematology</i> , 2008, 142, 854-856.	2.5	2
71	Negative impact of FLT3 abnormalities in elderly acute myeloid leukemia patients. <i>Leukemia and Lymphoma</i> , 2008, 49, 994-997.	1.3	8
72	Clinical and biological features of acute promyelocytic leukemia patients developing retinoic acid syndrome during induction treatment with all-trans retinoic acid and idarubicin. <i>Haematologica</i> , 2008, 93, 1918-1920.	3.5	17

#	ARTICLE	IF	CITATIONS
73	Improving outcomes of acute invasive <i>Aspergillus</i> rhinosinusitis in patients with hematologic malignancies or aplastic anemia: the role of voriconazole. <i>Haematologica</i> , 2008, 93, 159-160.	3.5	6
74	Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Already Harbor Bcr-Abl Kinase Domain Mutations at Low Levels at the Time of Diagnosis - a Report by the GIMEMA ALL Working Party. <i>Blood</i> , 2008, 112, 722-722.	1.4	4
75	Haemolytic uremic syndrome during induction therapy in an acute promyelocytic leukemia patient with aberrant phenotype: A possible manifestation of retinoic acid syndrome. <i>Leukemia and Lymphoma</i> , 2007, 48, 833-834.	1.3	2
76	Late Relapses in Acute Promyelocytic Leukaemia. <i>Acta Haematologica</i> , 2007, 117, 106-108.	1.4	17
77	Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocytic leukemia. <i>Haematologica</i> , 2007, 92, 1273-1274.	3.5	49
78	ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. <i>Blood</i> , 2007, 109, 5473-5476.	1.4	46
79	Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. <i>Blood</i> , 2007, 109, 3676-3678.	1.4	336
80	Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features. <i>Leukemia</i> , 2007, 21, 79-83.	7.2	108
81	Epigenetic Silencing of the Myelopoiesis Regulator microRNA-223 by the AML1/ETO Oncoprotein. <i>Cancer Cell</i> , 2007, 12, 457-466.	16.8	373
82	Prolonged molecular remission in a newly diagnosed acute promyelocytic leukaemia with a severe cardiomyopathy using low-dose gemtuzumab ozogamicin and all-trans retinoic acid. <i>Annals of Hematology</i> , 2007, 86, 295-297.	1.8	2
83	Dasatinib as Front-Line Monotherapy for the Induction Treatment of Adult and Elderly Ph+ Acute Lymphoblastic Leukemia (ALL) Patients: Interim Analysis of the GIMEMA Prospective Study LAL1205.. <i>Blood</i> , 2007, 110, 7-7.	1.4	16
84	Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol. <i>Blood</i> , 2006, 107, 473-479.	1.4	109
85	Sequential Valproic Acid/All-trans Retinoic Acid Treatment Reprograms Differentiation in Refractory and High-Risk Acute Myeloid Leukemia. <i>Cancer Research</i> , 2006, 66, 8903-8911.	0.9	125
86	<i>Aspergillus</i> Galactomannan Enzyme-Linked Immunosorbent Assay Cross-Reactivity Caused by Invasive <i>Geotrichum capitatum</i> . <i>Journal of Clinical Microbiology</i> , 2006, 44, 3432-3434.	3.9	82
87	The role of BCR/ABL isoforms in the presentation and outcome of patients with Philadelphia-positive acute lymphoblastic leukemia: a seven-year update of the GIMEMA 0496 trial. <i>Haematologica</i> , 2006, 91, 377-80.	3.5	32
88	A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. <i>Blood</i> , 2005, 105, 3434-3441.	1.4	178
89	BAVC regimen and autologous bone marrow transplantation for APL patients in second molecular remission: updated results. <i>Bone Marrow Transplantation</i> , 2005, 36, 83-84.	2.4	7
90	Biclonal blast crisis with a mutated ABL catalytic domain in a Ph, del (9q)-positive CML patient responsive to imatinib: drug resistance should be monitored in all patients irrespective of response status. <i>Leukemia</i> , 2005, 19, 287-289.	7.2	2

#	ARTICLE	IF	CITATIONS
91	CD1d expression on B-precursor acute lymphoblastic leukemia subsets with poor prognosis. <i>Leukemia</i> , 2005, 19, 551-556.	7.2	49
92	Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia. <i>Leukemia</i> , 2005, 19, 628-635.	7.2	85
93	CLZ gene rearrangements in acute leukemia: report of a diagnostic FISH assay and clinical features of nine patients. <i>Leukemia</i> , 2005, 19, 1696-1699.	7.2	36
94	Effects of hydration with salt repletion on renal toxicity of conventional amphotericin B empirical therapy: a prospective study in patients with hematological malignancies. <i>Supportive Care in Cancer</i> , 2005, 13, 987-992.	2.2	22
95	Repeated rituximab maintenance courses in fludarabine-failed young patients with chronic lymphocytic leukaemia responding to FAND chemotherapy. <i>The Hematology Journal</i> , 2004, 5, 186-187.	1.4	5
96	Retrospective comparison of qualitative and quantitative reverse transcriptase polymerase chain reaction in diagnosing and monitoring the ALL1-AF4 fusion transcript in patients with acute lymphoblastic leukaemia. <i>Leukemia</i> , 2004, 18, 1824-1830.	7.2	5
97	Recovery of Chronic Renal Impairment With Sirolimus After Lung Transplantation. <i>Annals of Thoracic Surgery</i> , 2004, 78, 1940-1943.	1.3	31
98	Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. <i>Blood</i> , 2004, 104, 1995-1999.	1.4	225
99	Valproic Acid Plus Retinoic Acid Induce Myeloid Differentiation in Chemotherapy-Resistant Acute Myeloid Leukemia Patients.. <i>Blood</i> , 2004, 104, 1805-1805.	1.4	1
100	Dramatic Improvement in CR Rate and CR Duration with Imatinib in Adult and Elderly Ph+ ALL Patients: Results of the GIMEMA Prospective Study LAL0201.. <i>Blood</i> , 2004, 104, 2739-2739.	1.4	10
101	Front-Line Treatment of Acute Promyelocytic Leukemia with AIDA Induction Followed by Risk-Adapted Consolidation: Results of the AIDA-2000 Trial of the Italian GIMEMA Group.. <i>Blood</i> , 2004, 104, 392-392.	1.4	30
102	MLL tandem duplication in two cases of acute myelocytic leukemia with unbalanced translocations. <i>Cancer Genetics and Cytogenetics</i> , 2003, 142, 8-12.	1.0	4
103	Trisomy 13 in a patient with common acute lymphoblastic leukemia: description of a case and review of the literature. <i>Cancer Genetics and Cytogenetics</i> , 2003, 144, 69-72.	1.0	7
104	Expression profiles of acute lymphoblastic and myeloblastic leukemias with ALL-1 rearrangements. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 7853-7858.	7.1	73
105	Clinico-biologic features and treatment outcome of adult pro-B-ALL patients enrolled in the GIMEMA 0496 study: absence of the ALL1/AF4 and of the BCR/ABL fusion genes correlates with a significantly better clinical outcome. <i>Blood</i> , 2003, 102, 2014-2020.	1.4	38
106	A multiplex reverse transcriptase-polymerase chain reaction strategy for the diagnostic molecular screening of chimeric genes: a clinical evaluation on 170 patients with acute lymphoblastic leukemia. <i>Haematologica</i> , 2003, 88, 275-9.	3.5	36
107	Intracardiac Thrombus in a Patient with Autoimmune Hemolytic Anemia Leading to a Diagnosis of Antiphospholipid Syndrome. <i>Acta Haematologica</i> , 2002, 107, 170-172.	1.4	3
108	Risk factors for nephrotoxicity associated with conventional amphotericin B therapy. <i>American Journal of Medicine</i> , 2002, 113, 351.	1.5	5

#	ARTICLE	IF	CITATIONS
109	MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. <i>Blood</i> , 2002, 100, 974-981.	1.4	99
110	Molecular cytogenetics characterization of a novel translocation involving chromosomes 17 and 19 in a Ph+ adult acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2002, 119, 488-491.	2.5	1
111	Upregulation of Meis1 and HoxA9 in acute lymphocytic leukemias with the t(4;11) abnormality. <i>Oncogene</i> , 2001, 20, 874-878.	5.9	154
112	Detection of BCR/ABL rearrangements in adult acute lymphoblastic leukemia using a highly sensitive interphase fluorescence in situ hybridization method (D-FISH). <i>The Hematology Journal</i> , 2001, 2, 54-60.	1.4	4
113	t(4;11)(q21;p15) translocation involving NUP98 and RAP1GDS1 genes: characterization of a new subset of T acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2000, 109, 788-793.	2.5	28
114	Idarubicin intensified BUCY2 regimen in allogeneic unmanipulated transplant for high-risk hematological malignancies. <i>Leukemia</i> , 2000, 14, 2052-2058.	7.2	8
115	Biological and therapeutic aspects of infant leukemia. <i>Blood</i> , 2000, 96, 24-33.	1.4	358
116	Myeloperoxidase gene expression in non-infant pro-B acute lymphoblastic leukaemia with or without ALL1/AF4 transcript. <i>British Journal of Haematology</i> , 2000, 111, 1065-1070.	2.5	8
117	Biological and therapeutic aspects of infant leukemia. <i>Blood</i> , 2000, 96, 24-33.	1.4	4
118	A prospective study of residual-disease monitoring of the ALL1/AF4 transcript in patients with t(4;11) acute lymphoblastic leukemia. <i>Blood</i> , 2000, 95, 96-101.	1.4	35
119	Biological and therapeutic aspects of infant leukemia. <i>Blood</i> , 2000, 96, 24-33.	1.4	102
120	Interstitial Insertion of AF10 into the ALL1 Gene in a Case of Infant Acute Lymphoblastic Leukemia. <i>Cancer Genetics and Cytogenetics</i> , 1998, 107, 107-110.	1.0	14
121	Sequential molecular monitoring of chimerism in chronic myeloid leukemia patients receiving donor lymphocyte transfusion for relapse after bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 1997, 19, 703-707.	2.4	30
122	Multigenetic lesions in infant acute leukaemias: correlations with ALL-1 gene status. <i>British Journal of Haematology</i> , 1997, 96, 308-313.	2.5	10
123	Infant acute leukemias show the same biased distribution of ALL1 gene breaks as topoisomerase II related secondary acute leukemias. <i>Cancer Research</i> , 1997, 57, 2879-83.	0.9	82
124	Precipitating <i>Pseudomonas aeruginosa</i> antibodies and antimicrobial therapy in cystic fibrosis patients. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1996, 15, 309-312.	2.9	0
125	Clinical relevance of residual disease monitoring by polymerase chain reaction in patients with ALL1/AF4 positive acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 1996, 92, 659-664.	2.5	39
126	Distribution of TP53 mutations among acute leukemias with MLL rearrangements. , 1996, 15, 48-53.		9

#	ARTICLE	IF	CITATIONS
127	Analysis of the BCL-6 gene configuration in diffuse B-cell non-Hodgkin's lymphomas and Hodgkin's disease. <i>Journal of Pathology</i> , 1995, 177, 21-25.	4.5	13
128	Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features. <i>Blood</i> , 1995, 85, 2685-2690.	1.4	107
129	p53 gene inactivation in acute lymphoblastic leukemia of B cell lineage associates with chromosomal breakpoints at 11q23 and 8q24. <i>Leukemia</i> , 1995, 9, 955-9.	7.2	16
130	ALL-1 gene rearrangements in acute myeloid leukemia: association with M4-M5 French-American-British classification subtypes and young age. <i>Cancer Research</i> , 1995, 55, 1625-8.	0.9	42
131	Prognostic relevance of ALL-1 gene rearrangement in infant acute leukemias. <i>Leukemia</i> , 1995, 9, 391-5.	7.2	47
132	ALL-1 gene at chromosome 11q23 is consistently altered in acute leukemia of early infancy. <i>Blood</i> , 1993, 82, 544-546.	1.4	109
133	ALL-1 gene at chromosome 11q23 is consistently altered in acute leukemia of early infancy. <i>Blood</i> , 1993, 82, 544-546.	1.4	30
134	ALL-1 gene at chromosome 11q23 is consistently altered in acute leukemia of early infancy. <i>Blood</i> , 1993, 82, 544-6.	1.4	8
135	Chemotherapy versus radiotherapy in early-stage Hodgkin's disease: Evidence of a more difficult rescue for patients relapsed after chemotherapy. <i>European Journal of Cancer</i> , 1992, 28, 1853-1855.	2.8	13
136	The t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to <i>Drosophila trithorax</i> , to the AF-4 gene. <i>Cell</i> , 1992, 71, 701-708.	28.9	821
137	Single Daily Dose Ceftriaxone Plus Amikacin Treatment of Febrile Episodes in Neutropenic Patients Attending Day Hospital for Hematologic Malignancies. <i>Oncology</i> , 1992, 49, 49-52.	1.9	30
138	An altered 11-kilobase transcript in leukemic cell lines with the t(4;11)(q21;q23) chromosome translocation. <i>Cancer Research</i> , 1992, 52, 3811-3.	0.9	36
139	Cloning of ALL-1, the locus involved in leukemias with the t(4;11)(q21;q23), t(9;11)(p22;q23), and t(11;19)(q23;p13) chromosome translocations. <i>Cancer Research</i> , 1991, 51, 6712-4.	0.9	136
140	Chemotherapy alone for the treatment of early-stage Hodgkin's disease. <i>European Journal of Cancer & Clinical Oncology</i> , 1990, 26, 1115-1118.	0.7	9
141	MOPP chemotherapy versus extended-field radiotherapy in the management of pathological stages I-IIA Hodgkin's disease. <i>Journal of Clinical Oncology</i> , 1989, 7, 732-737.	1.6	37
142	The Role of Restaging Laparotomy in Hodgkin'S Disease. <i>Acta OncolÃ³gica</i> , 1989, 28, 659-662.	1.8	1
143	Immune-deficiency in Hodgkin's disease (HD): a study of patients and healthy relatives in families with multiple cases. <i>European Journal of Cancer & Clinical Oncology</i> , 1988, 24, 1595-1601.	0.7	19
144	Sequential Combination Chemotherapy of High-Grade Non-Hodgkin's Lymphoma with 5-Fluorouracil, Methotrexate, Cytosine-Arabinoside, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (F-MACHOP). <i>Cancer Investigation</i> , 1987, 5, 159-169.	1.3	29

#	ARTICLE	IF	CITATIONS
145	Evaluation of therapeutic modalities in the control of hodgkin's disease. International Journal of Radiation Oncology Biology Physics, 1986, 12, 1617-1620.	0.8	18
146	A case of Burkitt lymphoma L_{3} ALL with t(8;14) translocation, developed 10 years after Hodgkin's disease. Scandinavian Journal of Haematology, 1985, 34, 97-100.	0.0	9
147	Acute leukaemia in patients treated for Hodgkin's disease. British Journal of Haematology, 1984, 58, 43-52.	2.5	55